Biogen Announces Webcast of Analyst & Investor Day Thursday, November 1, 2001, at 9:00 a.m. ET.Business Editors CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 31, 2001 Biogen, Inc. (Nasdaq:BGEN BGen abbr. brigadier general ) will hold its Analyst & Investor Day on Thursday, November 1, 2001, at 9:00 a.m. Eastern Time. This call is being webcast by CCBN CCBN Central Coast Bancorp CCBN Charles County Business Network and can be accessed via Biogen's web site (http://www.biogen.com/). Biogen, Inc., winner of the U.S. National Medal of Technology, is a biopharmaceutical company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in Cambridge, MA, the Company's revenues are generated from international sales of AVONEX (Interferon beta interferon beta Fibroblast interferon IFN-β A 20 kD anti-viral protein with 30% 'homology' with IFN alpha, encoded on chromosome 9, produced by fibroblasts in response to viruses or polyribonucleotides 1-a) for treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen's research and development activities are focused on novel products to treat inflammatory and autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause , neurological diseases, cancer, fibrosis and congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. . The Company maintains active clinical research programs in protein therapeutics, small molecules, genomics and gene therapy. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion